DGAP-Adhoc: BRAIN Biotech AG: BRAIN Group expands its food enzyme business with the acquisition of a majority of Breatec B.V. and Comix
|
DGAP-Ad-hoc: BRAIN Biotech AG / Key word(s): Takeover
BRAIN Biotech AG: BRAIN Group expands its food enzyme business with the acquisition of a majority of Breatec B.V. and Comix
01-Feb-2022 / 17:36 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
BRAIN Group expands its food enzyme business with the acquisition of a majority of Breatec B.V. and Comix
Zwingenberg, Germany, February 1st, 2022. BRAIN Biotech AG ("BRAIN") has acquired an initial stake of 62% in Breatec B.V. including the Comix business via Weriol Group B.V., Nieuwkuijk, Netherlands, to expand its food related enzyme business. A call/put structure has been negotiated to aquire the business in full latest until the end of the first quarter 2027. The initial purchase price is EUR 3.7 million and will be financed out of existing cash. Breatec B.V. had a turnover of around EUR 7.0 million in calendar year 2021 and was EBITDA positive.
Notifying person:
Michael Schneiders, Head of IR & Sustainability
BRAIN Biotech AG
Darmstädter Str. 34-36, 64673 Zwingenberg, Germany
www.brain-biotech.com
Investor Relations Office
Phone: +49-(0)-6251-9331-0
Fax: +49-(0)-6251-9331-11
Mail: [email protected]
End of ad hoc announcement
Information and Explanation of the Issuer to this News:
About BRAIN
BRAIN Biotech AG ('BRAIN') is a leading European industrial biotechnology specialist with a focus on nutrition, health and the environment. As a technology and solutions provider the company supports the biologization of industries with bio-based products and processes. From contract R&D with industrial partners to advancing own disruptive incubator projects and customized enzyme products, BRAIN's broad cutting-edge biotech expertise and its agile teams are key to success.
BRAIN Biotech AG, Germany, is the parent company of the international BRAIN Group, distributing specialty B2B products like enzymes or bioactive natural products. The BRAIN Group has its own fermentation or production facilities in Germany, UK and the US, which together with the associated biotechnological solution competency complete the value chain within the group.
As a Participant of the United Nations Global Compact, BRAIN Biotech AG is committed to aligning strategies and operations with universal principles on human rights, labour, environment and anti-corruption and to actively advance common societal goals. Our products and services target at least five of the UN SDGs directly.
Since its IPO in 2016, BRAIN Biotech AG is listed in the Prime Standard of the Frankfurt Stock Exchange (ISIN DE0005203947 / WKN 520394).
01-Feb-2022 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de
|
| Language: |
English |
| Company: |
BRAIN Biotech AG |
|
Darmstädter Straße 34-36 |
|
64673 Zwingenberg |
|
Germany |
| Phone: |
+49 (0) 62 51 / 9331-0 |
| Fax: |
+49 (0) 62 51 / 9331-11 |
| E-mail: |
[email protected] |
| Internet: |
www.brain-biotech.com |
| ISIN: |
DE0005203947 |
| WKN: |
520394 |
| Listed: |
Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange |
| EQS News ID: |
1275447 |
| |
| End of Announcement |
DGAP News Service |
1275447 01-Feb-2022 CET/CEST
|
Die wichtigsten Finanzdaten auf einen Blick
|
| |
2017 |
2018 |
2019 |
2020 |
2021 |
2022 |
2023e |
| Umsatzerlöse1 |
24,11 |
27,05 |
38,56 |
38,23 |
38,39 |
45,51 |
55,34 |
| EBITDA1,2 |
-7,70 |
-6,55 |
-2,50 |
-3,88 |
-2,53 |
-1,31 |
-0,83 |
| EBITDA-Marge3 |
-31,94 |
-24,21 |
-6,48 |
-10,15 |
-6,59 |
-2,88 |
|
| EBIT1,4 |
-9,37 |
-9,57 |
-7,20 |
-8,23 |
-6,55 |
-5,65 |
-5,48 |
| EBIT-Marge5 |
-38,86 |
-35,38 |
-18,67 |
-21,53 |
-17,06 |
-12,42 |
-9,90 |
| Jahresüberschuss1 |
-9,40 |
-8,37 |
-11,12 |
-9,02 |
-4,68 |
-6,34 |
-8,11 |
| Netto-Marge6 |
-38,99 |
-30,94 |
-28,84 |
-23,59 |
-12,19 |
-13,93 |
-14,66 |
| Cashflow1,7 |
-5,80 |
-5,42 |
-3,38 |
-4,77 |
-3,10 |
-1,49 |
-4,22 |
| Ergebnis je Aktie8 |
-0,58 |
-0,45 |
-0,61 |
-0,52 |
-0,25 |
-0,30 |
-0,38 |
| Dividende8 |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
Quelle: boersengefluester.de und Firmenangaben
Geschäftsbericht 2023 - Kostenfrei herunterladen. 
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de
Wirtschaftsprüfer: Baker Tilly
|
| INVESTOR-INFORMATIONEN |
| ©boersengefluester.de |
| BRAIN Biotech |
| WKN |
Kurs in € |
Einschätzung |
Börsenwert in Mio. € |
| 520394 |
2,780 |
Halten |
60,74 |
| KGV 2025e |
KGV 10Y-Ø |
BGFL-Ratio |
Shiller-KGV |
| 27,80 |
0,00 |
0,00 |
-6,04 |
| KBV |
KCV |
KUV |
EV/EBITDA |
| 2,79 |
- |
1,10 |
-103,29 |
| Dividende '22 in € |
Dividende '23e in € |
Div.-Rendite '23e
in % |
Hauptversammlung |
| 0,00 |
0,00 |
0,00 |
12.03.2024 |
| Q1-Zahlen |
Q2-Zahlen |
Q3-Zahlen |
Bilanz-PK |
| 28.02.2024 |
28.05.2024 |
29.08.2024 |
17.01.2024 |
| Abstand 60Tage-Linie |
Abstand 200Tage-Linie |
Performance YtD |
Performance 52 Wochen |
| -21,65% |
-29,64% |
-24,04% |
-53,20% |
|
|
BRAIN Biotech AG DE0005203947